{"entity":{"id":"nct07598955","kind":"trial","name":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","aka":["SELECT-NK-THYM"],"tldr":"A phase 1/2 trial of Cyclophosphamide, Fludarabine and EB-CAR30-NK in thymoma and thymic carcinoma, run by Beijing Biotech, now recruiting.","summary":"Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma is a phase 1/2 interventional study registered as NCT07598955 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-06-14. Interventions recorded: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK and Rimiducid (AP1903).","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07598955","url":"https://clinicaltrials.gov/study/NCT07598955"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["thymic-epithelial","thymoma","thymic-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","fludarabine","eb-car30-nk"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07598955","phase":"1/2","setting":"A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic Carcinoma","sponsor":"Beijing Biotech","participation":[{"nct":"NCT07598955","source":"https://clinicaltrials.gov/study/NCT07598955","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"070fd2398af37f625d2d12e40867b0ef6718f11561cf93d447b618b5106c9cdd","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-20","leadSponsor":"Beijing Biotech","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":36,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-02","startedType":"actual","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07598955/","neighbours":{"cancer":[{"id":"thymic-carcinoma","kind":"cancer","name":"Thymic carcinoma","route":"/cancers/thymic-carcinoma/"},{"id":"thymoma","kind":"cancer","name":"Thymoma (WHO types A, AB, B1, B2 and B3)","route":"/cancers/thymoma/"},{"id":"thymic-epithelial","kind":"cancer","name":"Thymoma and thymic carcinoma","route":"/cancers/thymic-epithelial/"}],"drug":[{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"eb-car30-nk","kind":"drug","name":"EB-CAR30-NK","route":"/drugs/eb-car30-nk/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}